151 related articles for article (PubMed ID: 35705274)
41. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
43. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
[TBL] [Abstract][Full Text] [Related]
44. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
[TBL] [Abstract][Full Text] [Related]
45. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
[TBL] [Abstract][Full Text] [Related]
46. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.
Ikoma H; Miyaoka M; Hiraiwa S; Yukie Kikuti Y; Shiraiwa S; Hara R; Kojima M; Ohmachi K; Ando K; Carreras J; Nakamura N
Pathol Int; 2022 Jun; 72(6):321-331. PubMed ID: 35297566
[TBL] [Abstract][Full Text] [Related]
49. Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH/BCL2 and the t(14;18)(q32;q21) IGH/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma?
Palmedo G; Hantschke M; Rütten A; Mentzel T; Kempf W; Tomasini D; Kutzner H
Am J Dermatopathol; 2007 Jun; 29(3):231-6. PubMed ID: 17519619
[TBL] [Abstract][Full Text] [Related]
50. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
51. Follicular lymphoma in Taiwan: a low frequency of t(14;18), with grade 3A tumours more closely related to grade 3B than to low-grade tumours.
Chang ST; Lu YH; Lu CL; Kuo SY; Liu H; Lin SH; Win KT; Hsieh YC; Chuang SS
Histopathology; 2013 Jul; 63(1):1-12. PubMed ID: 23631722
[TBL] [Abstract][Full Text] [Related]
52. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
53. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation.
Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Banham AH; Ventura R; Matsumoto T; Iida M; Ohji Y; Yao T; Tsuneyoshi M; Du MQ
Gut; 2007 Oct; 56(10):1358-63. PubMed ID: 17525089
[TBL] [Abstract][Full Text] [Related]
54. Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes.
Kikuchi A; Nakamura N; Kuze T; Sasaki Y; Abe M; Ohno H; Akasaka T; Nakamura S; Ohshima K; Ando K
Leuk Res; 2008 Aug; 32(8):1176-82. PubMed ID: 18460403
[TBL] [Abstract][Full Text] [Related]
55. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
56. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
Pina-Oviedo S; Bellamy WT; Gokden M
Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
[TBL] [Abstract][Full Text] [Related]
57. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
58. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
[TBL] [Abstract][Full Text] [Related]
59. Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.
Ohno H; Nakagawa M; Kishimori C; Fukutsuka K; Maekawa F; Takeoka K; Hayashida M; Sakamoto S; Akasaka T; Honjo G
Hematol Oncol; 2020 Apr; 38(2):171-180. PubMed ID: 31955451
[TBL] [Abstract][Full Text] [Related]
60. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
